Source: International Congress 2016 – Infections, sepsis, and pulmonary embolism
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Annia Fleur Schreiber (Turin, Italy), Annia Fleur Schreiber, Hannan Arana, Xiao Lu, Alexandra Aubry, Jie Lv, Jean-Jacques Rouby, Olivier Langeron, Qin Lu. LATE-BREAKING ABSTRACT: Nebulized versus intravenous amikacin in ventilator-associated pneumonia Caused by pseudomonas aeruginosa. Eur Respir J 2016; 48: Suppl. 60, 363

Member's Comments

No comment yet.

Related content which might interest you: ICU acquired pneumonia due to pseudomonas aeruginosa with and without multidrug resistance Source: International Congress 2014 – ICU outcomes, sepsis and infections Year: 2014 Aerosolized colistin in critically ill patients for the treatment of ventilator-associated pneumonia, due to multidrug-resistant gram-negative bacteria Source: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006 Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 Multidrug resistant acinetobacter baumanii pneumonia: Mortality analysis and comparison of intravenous versus aerosolized therapy Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Effect of acenitobacter baumanii positive pneumonia on morbidity and mortality of patients Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013 Colistin therapy for nosocomial pneumonia and nephrotoxicity Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Aerosolised treatment for VAP Source: Eur Respir Mon 2011; 53: 54-65 Year: 2011 Nebulised colistin for ventilator-associated pneumonia prevention Source: Eur Respir J 2015; 46: 1732-1739 Year: 2015 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Ventilator-associated pneumonia (VAP) pathogenic microorganisms eradication and persistence during antimicrobial therapy Source: Annual Congress 2013 –Recent developments in pneumonia Year: 2013 Delirium induced by clarithromycin in a patient with community-acquired pneumonia Source: Eur Respir J 2006; 28: 671-672 Year: 2006 Predictors of treatment failure in patients with bacteremic pneumococcal community-acquired pneumonia Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Multidrug resistant acinetobacter baumannii in ventilator associated pneumonia: Prevalence and predictors of mortality Source: International Congress 2014 – ICU outcomes, sepsis and infections Year: 2014 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Reducing antibiotics use for ventilator-associated pneumonia in brain-injured patients Source: Eur Respir J 2016; 47: 1060-1061 Year: 2016 Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Community-acquired pneumonia with severe sepsis: Etiology and prognosis Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Treatment of nosocomial pneumonia with piperacillin-tazobactam Source: Eur Respir J 2007; 30: Suppl. 51, 53s Year: 2007 LATE-BREAKING ABSTRACT: Oral solithromycin has a favorable profile versus oral moxifloxacin for treatment of adult community-acquired pneumonia (CABP) in elderly patients and those with COPD or asthma Source: International Congress 2015 – Respiratory infections: from basic science to clinical issues Year: 2015